Services In Health Economics SHE, Brussels, Belgium
HEOR, argenx, Boston, Massachusetts, USA.
BMJ Open. 2023 Jan 31;13(1):e066445. doi: 10.1136/bmjopen-2022-066445.
Myasthenia gravis (MG) is a rare, chronic, autoimmune neuromuscular disease which can affect functional and mental aspects of health and health-related quality of life (HRQoL). This study aims to obtain detailed knowledge of the impact of MG on HRQoL in a broad population from the perspective of the patient.
Prospective, observational, digital, longitudinal real-world study.
Adult patients with MG from seven countries (USA, Japan, Germany, UK, Italy, Spain and Canada) downloaded a mobile application onto their phones and entered data about themselves and their MG.
Data was collected using the following general and disease-specific patient-reported outcome measurements: EuroQol 5 Domains Health-Related Quality of Life Questionnaire (EQ-5D-5L), Myasthenia Gravis Activities of Daily Living (MG-ADL), Myasthenia Gravis Quality of Life 15-item revised scale (MG-QoL-15r), Hospital Anxiety and Depression Scale (HADS) and Health Utilities Index III (HUI3). Patients were categorised by their self-assessed Myasthenia Gravis Foundation of America (MGFA) class (I-V).
Baseline results of 841 participants (mean age 47 years, 70% women) are reported . The distribution across the MGFA classes was: 13.9%, 31.0%, 38.1%, 15.5% and 1.6% for classes I-V. The MGFA class was a strong predictor of all aspects of HRQoL, measured with disease-specific and with generic instruments. The domains in which patients with MG most frequently mentioned problems were usual activities, anxiety and depression, tiredness, breathing and vision. The mean total MG-ADL Score was positively associated with increasing MGFA classes: 2.7, 4.4, 6.3 and 8.4 for MGFA classes I-IV. Mean baseline EQ-5D-5L utility was also associated with MGFA classes and was 0.817, 0.766, 0.648 and 0.530 for MGFA class I-IV.
MG has a large impact on key aspects of health and HRQoL. The impact of this disease increases substantially with increasing disease severity.
重症肌无力(MG)是一种罕见的慢性自身免疫性神经肌肉疾病,可影响健康和健康相关生活质量(HRQoL)的功能和心理方面。本研究旨在从患者角度获得广泛人群中 MG 对 HRQoL 影响的详细知识。
前瞻性、观察性、数字化、纵向真实世界研究。
来自七个国家(美国、日本、德国、英国、意大利、西班牙和加拿大)的成年 MG 患者将移动应用程序下载到他们的手机上,并输入有关自己和 MG 的数据。
使用以下一般和疾病特异性患者报告的结局测量收集数据:欧洲五维健康量表(EQ-5D-5L)、重症肌无力日常生活活动量表(MG-ADL)、重症肌无力生活质量 15 项修订量表(MG-QoL-15r)、医院焦虑和抑郁量表(HADS)和健康效用指数 III(HUI3)。根据患者自我评估的美国重症肌无力基金会(MGFA)分级(I-V)对患者进行分类。
报告了 841 名参与者的基线结果(平均年龄 47 岁,70%为女性)。MGFA 分级的分布情况为:I 级占 13.9%,II 级占 31.0%,III 级占 38.1%,IV 级占 15.5%,V 级占 1.6%。MGFA 分级是 HRQoL 所有方面的有力预测指标,包括疾病特异性和通用仪器测量的方面。MG 患者最常提到的问题的领域是日常活动、焦虑和抑郁、疲劳、呼吸和视力。MG-ADL 总评分的平均值与 MGFA 分级呈正相关:MGFA I-IV 级分别为 2.7、4.4、6.3 和 8.4。基线平均 EQ-5D-5L 效用也与 MGFA 分级相关,MGFA I-IV 级分别为 0.817、0.766、0.648 和 0.530。
MG 对健康和 HRQoL 的关键方面有很大影响。随着疾病严重程度的增加,这种疾病的影响会大大增加。